16. Pooled analysis of clinical and technical success rates (54 trials – 1198 patients) Sebastian S et al. Am J Gastroenterol 2004 Group Number Cumulative Range Technical success Overall 1198 93% 64-100 Palliative 791 93% 67-100 Bridge to surgery 407 92% 33-100 Clinical success Overall 1198 89% 55-100 Palliative 791 91% 62-100 Bridge to surgery 407 72% 45-84
21. There is concern about risk of perforation Van Hooft J et al Endoscopy 2008
22. Author Journal Pts Palliation/ BTS Type of stent Complications (%) Perforations (%) Law WL Colorectal Dis 2010 130 101/29 Esoph.Wallstent Colon Wallflex Choostent Enteral Wallstent Ultraflex 20 1,5 Baraza W. Colorectal Dis 2008 63 56/7 Niti-S Bard Memotherm 25 0 M. Alcantara Tech Coloproctol 2007 95 (103 SEMS) 28/67 Enteral Wallstent Esophacoil Hanaro stent Wallflex 13.7 4.2 Giovannini MD J clin Gastroenterol 2008 36 (52 SEMS) 36/0 Choostent Wallstent Hanaro stent 35 7.5 Brehant O Colorectal Dis 2009 30 0/30 Wallflex 23 7 Min Kyu Jung Surg Endosc 2009 39 39/0 Niti-S Hanarostent Wallflex Early 12.8 Late 11.8 Early 2.6 Late 2.9 S. Mucci-Hennekinne Surg Endosc 2007 67 55/12 Hanarostent ? 6,2 Repici A Gastroint Endosc 2008 42 23/19 Wallflex Early 9.5 Late 14.3 2.4 Jong Pil Im Int J Colorectal Dis 2008 49 pts (51SEMS) 49/0 Hanaro MI Tech 24 2
23. Small AJ et al. GIE 2010 Bevacizumab-based therapies and Colonic perforation after SEMS placement Is it time for a warning? Bevacizumab-based therapies Treated Untreated P 15.4% 6.8% 0.06